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One sentence summary: NAT10 inhibition normalizes HGPS through TNPO1 24 
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ABSTRACT 25 
Hutchinson-Gilford progeria syndrome (HGPS) is an incurable premature ageing 26 
disease. Identifying deregulated biological processes in HGPS might thus help define 27 
novel therapeutic strategies. Recently, HGPS cells were shown to display abnormal 28 
nucleo-cytoplasmic transport and defects in the RanGTP gradient that mediates this. 29 
However, the mechanism behind these defects was not known. Here, we report that 30 
microtubule stabilisation in HGPS cells sequesters the non-classic nuclear import 31 
protein Transportin-1 in the cytoplasm, affecting the nuclear localisation of its cargos, 32 
including the nuclear pore protein NUP153. Consequently, nuclear Ran, nuclear 33 
anchorage of the nucleoporin Translocated Promoter Region (TPR) and chromatin 34 
organisation are disrupted, deregulating gene expression and inducing senescence. We 35 
show that inhibiting N-acetyltransferase 10 (NAT10) ameliorates HGPS phenotypes by 36 
rebalancing the nuclear to cytoplasmic ratio of Transportin-1. This restores nuclear-37 
pore-complex integrity and nuclear Ran localisation, thereby correcting HGPS cellular 38 
phenotypes. We observed a similar mechanism in cells from normal aged individuals. 39 
This study identifies a nuclear import pathway affected in ageing and underscores the 40 
potential for NAT10 inhibition as a possible therapeutic strategy for HGPS, and perhaps 41 




Hutchinson-Gilford progeria syndrome (HGPS) is a very rare, fatal premature ageing 45 
syndrome caused by a de novo heterozygous point mutation within exon 11 of the 46 
LMNA gene (1,2). LMNA encodes two type V intermediate filament proteins: lamin A 47 
and lamin C. Together with B-type lamins, these proteins form the nuclear lamina at 48 
the inner nuclear membrane, where they act as a scaffold to maintain nuclear 49 
architecture, nuclear pore complexes and chromatin organisation, and to regulate DNA 50 
replication and transcription. In HGPS, the mutation only affects lamin A and triggers 51 
the expression of a shorter, toxic form of the protein called progerin that acts as a 52 
dominant negative. Accumulation of progerin at the inner nuclear membrane alters 53 
nuclear lamina structure, causing abnormal nuclear morphology, aggregation of nuclear 54 
pore complexes, chromatin disorganisation due to loss of peripheral heterochromatin 55 
anchorage and transcriptional deregulation, ultimately leading to DNA damage 56 
accumulation and premature entry of HGPS cells into senescence (3-6). These cellular 57 
phenotypes are also observed in aged normal cells. In HGPS patients, progerin 58 
accumulation triggers segmental premature ageing, usually starting within the first year 59 
of life and leading to death at the average age of 14, mainly due to heart defects (7,8). 60 
Although HGPS syndrome was first described over a century ago, the exact 61 
mechanisms by which progerin expression drives such striking cellular and organismal 62 
phenotypes are still being explored.  63 
 64 
Various studies have reported disruption of nucleo-cytoplasmic transport in HGPS 65 
fibroblasts, due to an abnormal RanGTP gradient (9-11). Ran is a small GTPase that 66 
shuttles between the cytoplasm and the nucleus. Ran cycles between GDP-bound and 67 
GTP-bound states (12), with conversion between these states being catalysed by 68 
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regulators in the cytoplasm (RanGAP – Ran GTPase-Activating Protein) (13) and 69 
nucleus (RCC1- Regulator of Chromatin Condensation 1) (14,15). Therefore, Ran is 70 
predominantly in its GTP bound form in the nucleus, and in its GDP bound form in the 71 
cytoplasm. This creates a RanGTP gradient across the nuclear envelope (16,17) that 72 
allows active transport of protein cargoes through nuclear pore complexes by a family 73 
of carrier proteins called karyopherins. In HGPS, progerin expression was shown to 74 
induce defects in Ran nuclear localisation. Consequently, nuclear import of proteins 75 
requiring Ran-dependent active transport through nuclear pores appeared more strongly 76 
affected than that of proteins passively diffusing through nuclear pores in these cells. 77 
This was indeed the case for the nucleoporin translocated promoter region (TPR) (9,10), 78 
a polypeptide of ~265 kDa that forms a homodimer and is thus one of the largest 79 
nucleoporins. TPR is the last protein assembled at the nuclear pore complex and its 80 
anchorage in the nuclear envelope requires the nuclear pore protein NUP153 (18,19). 81 
Recently, we showed that disrupting NUP153 abundance or function affects Ran 82 
nuclear localisation, thus impairing nuclear import of 53BP1, involved in DNA damage 83 
repair. This contributed to DNA damage accumulation in ageing vascular smooth 84 
muscle cells (VSMCs) (20). Given that we had shown previously that Remodelin, a 85 
small-molecule inhibitor of N-acetyltransferase 10 (NAT10) protein normalises 86 
phenotypes of HGPS cells (21), we tested its effects on VSMCs. We observed that 87 
NAT10 inhibition restored NUP153 localisation and normalised nuclear Ran 88 
abundance in these cells through an uncharacterised mechanism (20). This raised the 89 
question as to why the abundance of nuclear Ran is altered in these cells and which 90 
aspect of nuclear transport machinery is disrupted, particularly as NUP153 can be 91 
imported by several import pathways (22-24). 92 
 93 
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Here, we show that the decrease of nuclear Ran abundance occurring in HGPS cells, as 94 
well as in cells from aged individuals, are linked to dysregulation of the non-classic 95 
transport pathway mediated by Transportin-1 (TNPO1), also called karyopherin β2 96 
(25). Unlike classical importin proteins, which are general transporters, TNPO1 only 97 
mediates the nuclear import of a subset of proteins. Among these, the most extensively 98 
characterised is the RNA binding protein heterogeneous nuclear ribonucleoprotein 1 99 
hnRNPA1 (26) that functions in several processes including mRNA biogenesis and 100 
promotion of transcription factor activity (27-29). More recently, nuclear pore complex 101 
protein NUP153 was characterised as a target for TNPO1-mediated nuclear import (24). 102 
Accordingly, we observed that hnRNPA1, NUP153, TPR and nuclear Ran defects in 103 
HGPS cells were linked to deregulation of the TNPO1 nuclear-to-cytoplasmic ratio. 104 
Notably, we established that NAT10 inhibition restored the TNPO1 pathway in HGPS 105 
cells, thereby enhancing nuclear localisation of its cargos such as hnRNPA1 and 106 
NUP153. This allowed proper binding of TPR to nuclear pore complex, chromatin 107 
reorganisation, and global gene transcription re-balancing, collectively preventing 108 
premature entry of HGPS cells into senescence. NUP153 depletion did not affect the 109 
Transportin-1 pathway, supporting the notion that TNPO1 deregulation in HGPS is the 110 
cause and not the consequence of abnormal NUP153 nuclear localisation.  This study 111 
thus provides mechanistic insight into how NAT10 inhibition reverses HGPS cellular 112 
phenotypes and provides further evidence that it may also be relevant in normal ageing. 113 
 114 
  115 
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RESULTS 116 
Premature ageing and normal aged cells display nucleocytoplasmic transport 117 
defects. 118 
We found by immunofluorescence staining that, as expected (30), most Ran was in the 119 
nuclei of interphase fibroblasts from a normal 20-year-old individual (Normal Fibro, 120 
Fig. 1A). By contrast, and in line with previous reports (9,10), we observed that Ran 121 
localization was abnormal in fibroblasts from an HGPS patient (HGPS 11513), with 122 
most Ran being cytoplasmic (Fig. 1A). Because evidence suggests that HGPS might 123 
recapitulate various aspects of normal ageing (31), we also looked at Ran sub-cellular 124 
localisation in fibroblasts from healthy individuals between 81 and 96 years-of-age 125 
(AG11240, AG04059, AG05248 and AG09602). Similarly to HGPS cells, nuclear Ran 126 
appeared to be depleted to various extents in cells from aged individuals (Fig. 1A). This 127 
was not associated with decreased Ran protein abundance in HGPS or in fibroblasts 128 
from aged individuals (Fig. 1B), suggesting that changes of Ran sub-cellular 129 
localisation reflected dysregulated RanGTP gradient formation across the nuclear 130 
envelope, rather than changes of Ran expression. As reported previously (10), 131 
decreased nuclear Ran in HGPS cells was also associated with decreased nuclear 132 
staining intensity of the nucleoporin TPR (Fig. 1C, D) as well as in cells from aged 133 
normal individuals (Fig. S1A, B). These results confirmed previous findings on HGPS 134 
cells and also suggested that a similar nucleo-cytoplasmic transport defect may occur 135 
during normal ageing. 136 
 137 
Inhibition of NAT10 re-balances nucleocytoplasmic transport. 138 
Because TPR requires the nuclear pore complex protein NUP153 to anchor it to the 139 
nuclear pore-complex basket (18), we assessed whether NUP153 was present at the 140 
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nuclear periphery by immunofluorescence in normal and in HGPS fibroblasts. We 141 
observed that NUP153 nuclear intensity was significantly decreased in HGPS cells 142 
compared to controls, in a manner that correlated with decreased nuclear TPR staining 143 
(Fig. 1E, F and Fig. S2A). Because we had previously reported that inhibition of N-144 
acetyltransferase protein NAT10 reverses abnormal phenotypes of HGPS cells as well 145 
as aged smooth-muscle cells (20,21), we investigated whether NAT10 inhibition 146 
affected NUP153 and TPR staining. Indeed, when we treated HGPS cells with the 147 
NAT10 inhibitor Remodelin (21), this increased nuclear staining intensity of NUP153 148 
and TPR (Fig. 1E, F). To assess whether this reflected an enhanced interaction between 149 
NUP153 and TPR proteins after Remodelin treatment, we performed a proximity 150 
ligation assay (PLA) that allows protein-protein interaction detection and quantification 151 
(32). In this assay, we used primary antibodies against TPR and NUP153, followed by 152 
incubation with a pair of secondary antibodies coupled to fluorescent labelled 153 
oligonucleotides. Following an enzymatic ligation and amplification reaction, proteins 154 
that are in close enough proximity (~30 nm) lead to the production of a fluorescent 155 
signal. While interaction between NUP153 and TPR was clearly detected in normal 156 
fibroblasts (Fig. 1G, green dots) it was almost completely absent in untreated HGPS 157 
cells, in accord with these proteins being abnormally localised. However, upon 158 
Remodelin treatment, the interaction between NUP153 and TPR was greatly enhanced 159 
(Fig. 1G). This suggested that NAT10 inhibition promoted normal nuclear localisation 160 
and anchorage of both NUP153 and TPR at the nuclear periphery of HGPS cells. 161 
 162 
We next looked at the effect of NAT10 inhibition on Ran sub-cellular localisation in 163 
HGPS cells. Strikingly, short-interfering RNA (siRNA) mediated depletion of NAT10 164 
(siNAT10), or NAT10 inhibition by Remodelin essentially completely abolished Ran 165 
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nuclear localisation defects in HGPS cells (Fig. 1H, I, Fig. S2B). In line with nuclear 166 
transport factor 2 (NTF2) mediating Ran nuclear import (33,34), siRNA depletion of 167 
NTF2 in normal fibroblasts decreased Ran nuclear intensity, similar to that observed in 168 
untreated HGPS cells (Fig. 1H, I). 169 
 170 
Ran disruption modifies chromatin compaction and triggers senescence. 171 
Because many cellular processes are disrupted in HGPS, we explored which might be 172 
associated with decreased nuclear Ran abundance. One of the phenotypes observed in 173 
HGPS cells is chromatin disorganisation and loss of heterochromatin marks including 174 
histone H3K9me3 (35,36). To assess whether disrupting Ran could affect chromatin 175 
state at the global level, we transfected non-progeric human cells with NTF2 siRNA 176 
(siNTF2; Fig. 2A) and looked at the effect on global chromatin compaction as measured 177 
by using DNA digestion by micrococcal nuclease (MNase). This established that 178 
disruption of nuclear Ran localisation led to global chromatin decompaction (Fig. 2B) 179 
and suggested that, by affecting the bi-directional transport of many large cargo 180 
proteins, Ran deregulation might have broad effects on chromatin organisation, as 181 
observed in HGPS (35,36). Chromatin relaxation was also observed – albeit to a lesser 182 
extent – upon TPR depletion, reflecting the known role of TPR and nuclear pore 183 
complexes in chromatin organisation at the nuclear periphery (37,38). 184 
 185 
We then assessed the effect of NTF2 depletion on the heterochromatin mark H3K9me3 186 
in normal fibroblasts, as well as in HGPS cells. We observed a marked decrease of 187 
H3K9me3 staining intensity upon NTF2 depletion in normal fibroblasts (Fig. 2C, D), 188 
similar to the basal level observed in HGPS cells (siCT). NTF2 depletion did not affect 189 
H3K9me3 further in HGPS cells. Moreover, we observed a similar decrease of 190 
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H3K9me3 in high passage number normal fibroblasts (P61), suggesting that the 191 
perturbation observed in HGPS cells resembles what happens when normal cells reach 192 
senescence. In addition to its effect on chromatin, disrupting nuclear Ran (siNTF2) also 193 
promoted the entry of normal fibroblasts into senescence as measured by senescence-194 
associated β-galactosidase staining (Fig. 2E, F). However, depleting NTF2 in HGPS 195 
cells that already had nuclear Ran defect did not significantly further increase the 196 
proportion of senescent cells. Collectively, these results suggested that deregulation of 197 
nuclear Ran observed in HGPS cells might, by globally affecting nucleocytoplasmic 198 
transport, contribute to downstream phenotypes of chromatin disorganisation and 199 
premature entry into senescence. 200 
 201 
NAT10 inhibition reverses Transportin-1 nuclear import pathway defects in 202 
HGPS cells. 203 
We showed recently that NUP153 disruption can affect nuclear Ran abundance (20). In 204 
light of this, and because NTF2 abundance or sub-cellular localisation do not appear to 205 
be affected in HGPS cells (Fig. S3A), we hypothesized that Ran gradient deregulation 206 
occurring in HGPS might reflect the loss of NUP153 nuclear import. This led us to 207 
investigate which upstream pathway(s) could affect NUP153 nuclear import in HGPS 208 
cells, especially since NUP153 can be imported by several proteins. However, recent 209 
evidence suggests that, in interphase cells, NUP153 is imported into the nucleus by the 210 
non-classic nuclear transport receptor Transportin-1 (TNPO1) (24), a karyopherin β 211 
protein that promotes nuclear import of only a specific subset of proteins, including 212 
NUP153 and hnRNPA1. We therefore assessed TNPO1 sub-cellular localization in 213 
normal and HGPS fibroblasts by immunofluorescence staining. While the nuclear-to-214 
cytoplasmic ratio of TNPO1 was ~1 in normal fibroblasts, TNPO1 was depleted from 215 
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the nucleus of HGPS cells (Fig. 3 A-B), similarly to what we had observed for Ran (Fig. 216 
1). To assess whether changes in the nuclear-to-cytoplasmic ratio of TNPO1 in HGPS 217 
cells had an impact on its nuclear import function, we assessed the sub-cellular 218 
localization of hnRNPA1, one of the best-described TNPO1 cargo proteins. In accord 219 
with TNPO1 pathway deficiency in HGPS cells, we observed a marked decrease of 220 
nuclear hnRNPA1 in such cells (Fig. 3A). Similar defects were observed for the Ewing 221 
Sarcoma protein EWS, another characterised TNPO1 cargo (39) (Fig. S3B, C). By 222 
contrast, the localization of NAT10, whose sub-cellular distribution is not detectably 223 
affected in HGPS (Fig. S4A and as described in (21)), was not altered upon interfering 224 
with TNPO1 function via expression of MBP-M9M, a peptide binding to TNPO1 and 225 
competing with its natural substrates (40) (Fig. S4B). These results thus highlight 226 
Tranportin-1 as a new pathway deregulated in HGPS. 227 
 228 
We also observed loss of nuclear TNPO1 in normal cells from aged individuals (Fig.  229 
3C), with no apparent change in abundance of TNPO1 or hnRNPA1 proteins, consistent 230 
with the HGPS cells (Fig. 3D). As NAT10 inhibition normalized NUP153 and TPR 231 
nuclear accumulation together with nuclear Ran abundance in HGPS cells (Fig. 1), we 232 
assessed its effects on the upstream Transportin-1 pathway. Both Remodelin treatment 233 
and NAT10 depletion (siNAT10) reverted the abnormal nuclear-to-cytoplasmic ratio 234 
of TNPO1 in HGPS cells to a level comparable to that of normal fibroblasts (Fig. 3 A-235 
B). Taken together, these results suggested that the Transportin-1 pathway is affected 236 
in HGPS cells as well as in normal cells from aged individuals, leading to defects in the 237 
nuclear import of TNPO1 and its cargos, including hnRNPA1 and NUP153, thereby 238 
contributing to downstream defects of the RanGTP gradient. We conclude that NAT10 239 
inhibition results in global normalisation of Transportin-1 sub-cellular localisation and 240 
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function in HGPS cells, thereby alleviating downstream phenotypes. Although TNPO1 241 
depletion itself reduces proliferation of normal RPE-1 cells (Fig. S5A), the Transportin-242 
1 pathway defects observed in HGPS and in ageing cells do not appear to be a mere 243 
consequence of slower cell growth. Indeed, mimicking reduced cell growth through 244 
serum starvation of normal cells (RPE-1 and normal fibroblasts) did not discernibly 245 
affect the Transportin-1 pathway, nor the subcellular localisation of Ran or H3K9me3 246 
(Fig. S5B-D) that are strongly affected in HGPS cells.  247 
 248 
Modulation of microtubule stability by NAT10 inhibition affects the Transportin-249 
1 pathway. 250 
We previously observed that HGPS fibroblasts display a more stable microtubule 251 
network than control cells (21), and that this contributes to abnormal HGPS cellular 252 
phenotypes. We also showed that NAT10 inhibition improved these phenotypes, at 253 
least in part by targeting and destabilizing microtubules, thus releasing external forces 254 
on the nucleus to normalize nuclear shape (21). This is in accord with a pool of NAT10 255 
being associated with the cytoskeleton, as observed by subcellular fractionation and 256 
immunofluorescence (Fig. S6A-B). To assess whether there was a link between 257 
accumulation of TNPO1 in the cytoplasm of HGPS cells and microtubule stability, we 258 
first performed a PLA assay between TNPO1 and alpha-Tubulin. This established that, 259 
despite similar TNPO1 and alpha-Tubulin staining intensities observed by 260 
immunofluorescence (Fig. S7A) and similar protein abundance observed by western 261 
blotting (Fig. S7B), the level of interaction between TNPO1 and alpha-Tubulin was 262 
significantly higher in HGPS than in normal fibroblasts, whether measured per cell or 263 
per set area of cytoplasm (Fig. 4A-B). The reason for measuring the number of PLA 264 
spots within a set area was to account for the fact that senescent cells are bigger, which 265 
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could have biased the results. However, there was a significant increased number of 266 
PLA spots even within the set area of cytoplasm (Fig. 4B right panel), showing that the 267 
increased interaction was not a reflection of the increased cell area. The interaction 268 
between TNPO1 and alpha-Tubulin was confirmed by immunoprecipitation using 269 
extracts of normal fibroblasts, for which we could obtain enough cells for such studies 270 
(Fig. S7C). 271 
 272 
Next, to understand whether the effects of NAT10 inhibition on TNPO1 was associated 273 
with microtubule stabilization, we treated normal and HGPS fibroblasts with the 274 
microtubule stabilizing or destabilizing agents tubacin or nocodazole, respectively (Fig. 275 
4C). Notably, mimicking microtubule stabilization, as occurs in HGPS cells, by treating 276 
normal fibroblasts with tubacin led to significant defects in both TNPO1 and hnRNPA1 277 
nuclear import (Fig. 4C-D). By contrast, destabilizing microtubules in HGPS cells or 278 
in normal cells from aged individuals with nocodazole enhanced TNPO1 nuclear 279 
localization, and presumably by promoting TNPO1 transport function, increased 280 
abundance of nuclear hnRNPA1 (Fig. 4C-D and Fig. S8). These results suggested that 281 
the Transportin-1 mediated import pathway can be altered by microtubule stability, and 282 
that by modulating this, NAT10 inhibition re-balanced the TNPO1 nuclear-to-283 
cytoplasm ratio and enhancing nuclear import of TNPO1 cargo proteins.  284 
 285 
NAT10 inhibition-mediated normalisation of HGPS cells requires TNPO1. 286 
To determine whether the normalization of heterochromatin markers and the decrease 287 
of senescence observed upon NAT10 inhibition in HGPS cells depended on 288 
Transportin-1, we treated normal or HGPS fibroblasts with siRNAs to deplete NAT10 289 
alone or in combination with NUP153 or TNPO1 depletion. As we observed previously 290 
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(20), NUP153 depletion in normal cells led to loss of nuclear Ran, probably because it 291 
affects the structure of nuclear pore complexes that are important for RanGTP gradient 292 
formation. However, NUP153 depletion did not affect the Transportin-1 pathway, as 293 
observed by the normal sub-cellular localisation of TNPO1 and its downstream target 294 
hnRNPA1 (Fig. S9). Cells impaired in nuclear Ran due to TNPO1 depletion (siTNPO1 295 
Fig. 5A, see cells highlighted by arrows and Fig. S10) or as observed in HGPS cells 296 
(siCT, Fig. 5B), also displayed significantly reduced levels of the heterochromatin 297 
marker H3K9me3 (Fig. 5C). This is in accordance with the chromatin decompaction 298 
that we observed upon Ran deregulation (Fig. 2B, C) and suggested that TNPO1 299 
depletion was sufficient to cause this phenotype. Furthermore, co-depletion of NUP153 300 
and NAT10 in normal fibroblasts (siNUP153+siNAT10) produced similar H3K9me3 301 
phenotypes compared to siNUP153 alone (Fig. 5A, C), identifying NUP153 as a critical 302 
mediator of NAT10-dependent cellular rebalancing. While NAT10 depletion alone 303 
restored nuclear Ran and H3K9me3 staining in HGPS cells, this did not happen when 304 
NUP153 or TNPO1 was co-depleted with NAT10 (Fig. 5B, C). Similarly, while NAT10 305 
depletion strongly decreased the proportion of cells positive for senescence-associated 306 
β-galactosidase in HGPS cells, this was not the case when NUP153 or TNPO1 was co-307 
depleted with NAT10 (Fig. 5D-E). These results indicated that normalization of 308 
phenotypes caused by NAT10 depletion in HGPS cells indeed occurred via restoration 309 
of TNPO1 pathway function (thus, when TNPO1 or its cargo NUP153 are absent, 310 
NAT10-dependent phenotypic rescue does not occur). TNPO1 or NUP153 depletion in 311 
normal fibroblasts also promoted senescence, implying that the Transportin-1 pathway 312 
is important to maintain cellular homeostasis under such settings.  313 
 314 
TNPO1 is required for NAT10 inhibition-mediated gene expression modulation. 315 
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In light of the above observations, we hypothesized that enhancing the Transportin-1 316 
pathway in HGPS cells via inhibiting NAT10 might have an impact on gene expression. 317 
To test this idea, we performed global gene-expression analysis on HGPS cells 318 
compared to normal fibroblasts, after 8 weeks of chronic Remodelin treatment (media 319 
was supplemented with fresh Remodelin every 3 days). Ensuing “volcano plots” of 320 
each individual differential expression analysis (Fig. 6A) show log10 adjusted p-values 321 
plotted against log2 fold gene-expression changes. Significant genes (based on a fold-322 
change threshold of 2-fold up or down and an adjusted p-value threshold of 0.05) are 323 
indicated by the red (increased expression) and blue (decreased expression) regions of 324 
the plots. As expected and as previously reported (31,35,41), we observed deregulation 325 
of gene expression in HGPS cells compared to normal fibroblasts (Fig. 6A left panel 326 
and Fig. 6B row 1), with 137 and 221 genes whose expression significantly increased 327 
or decreased respectively. Notably, chronic long-term treatment with Remodelin had 328 
very little effect on gene expression in normal fibroblasts, with only 17 genes whose 329 
expression significantly increased or decreased (Fig. 6A middle panel). In marked 330 
contrast, Remodelin had a strong effect on HGPS cells (Fig. 6A right panel), modifying 331 
the expression of 652 genes (Table S1). Strikingly, these Remodelin-induced gene-332 
expression changes in HGPS cells were largely reciprocal to the gene expression 333 
differences between HGPS cells and normal cells (Fig. 6B; compare row 2 with row 1). 334 
Thus, long-term Remodelin treatment had a strong rebalancing effect on the expression 335 
of most genes deregulated in HGPS cells. 336 
 337 
Next, we asked whether the gene expression changes mediated by NAT10 inhibition 338 
would still occur in the absence of TNPO1. To address this question, we performed a 339 
separate analysis following short term depletion of NAT10 and/or TNPO1 by siRNA. 340 
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We used NAT10 siRNA (instead of Remodelin) to enable rigorous comparison to 341 
siRNA-mediated depletion of TNPO1. Due to the shorter timeframe of siRNA 342 
experiments, we applied a lower threshold (1.5-fold up or down) in this analysis, which 343 
increased the number of deregulated genes in control (siCT) HGPS cells (Fig. 6C, left 344 
panel) compared to earlier experiments with Remodelin (Fig. 6A, left panel). Similar 345 
to Remodelin treatment, NAT10 depletion modified the expression of more genes in 346 
HGPS cells than it did in normal fibroblasts (Fig. 6C, middle and right panel and Table 347 
S2). It did, however, have a stronger impact on normal fibroblasts than Remodelin. 348 
Indeed, NAT10 depletion via siRNA abolishes all functions of NAT10 such as its RNA 349 
helicase activity and its role in ribosome biogenesis (42). Even though we did observe 350 
a rebalancing effect on some HGPS deregulated genes (Fig. 6D), short-term NAT10 351 
depletion via siRNA treatment did not have comparable effects to Remodelin treatment 352 
on global gene expression rebalancing (Fig. 6D row 2 vs row 1). This suggests that 353 
long-term NAT10 inhibition is required to observe global rebalancing of HGPS gene 354 
expression profile.  355 
 356 
To assess whether NAT10 depletion-mediated gene expression changes were occurring 357 
through TNPO1, we compared NAT10 depletion alone with co-depletion of NAT10 358 
and TNPO1 (Fig. 7A). We observed that 70% of the genes whose expression 359 
significantly increased or decreased upon NAT10 depletion alone in normal fibroblasts 360 
were not modified anymore upon co-depletion with TNPO1 (Fig. 7B, red only genes, 361 
Tables S3-4), despite similar level of NAT10 protein knock-down (Fig. 7A). In HGPS 362 
cells, this number was reduced to 40% (Fig. 7C), likely a result of the deregulation of 363 
additional pathways. However, since we observed that the TNPO1 pathway was 364 
required for the NAT10 inhibition-mediated phenotypic changes in HGPS cells, we 365 
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hypothesized that this specific set of genes (Fig. 7C, red only genes) would be mainly 366 
responsible for the HGPS cellular rescue. Gene ontology analysis of those genes 367 
significantly affected by NAT10 depletion only (Table S5) and not by co-depletion with 368 
TNPO1 in HGPS cells showed an enrichment for various cellular components (CC, Fig. 369 
7D) including cell substrate junction and focal adhesion, extracellular matrix or 370 
endoplasmic reticulum for genes whose expression was decreased (blue), or Golgi and 371 
small ribosomal subunits for genes whose expression was increased (red). When 372 
plotting this specific set of genes that we refer to as “siNAT10 only” on a heatmap (Fig. 373 
7E row 1 – corresponding to Fig. 7C, red only genes), we observed that the expression 374 
of about 40% of this specific set of genes was rebalanced towards the expression 375 
observed in normal fibroblasts (Fig. 7E compare genes with opposite colours in row 2 376 
vs row 1).  377 
 378 
Then, to assess whether the TNPO1 pathway was affected in HGPS, we compared the 379 
effect of TNPO1 depletion on gene expression profiles in normal fibroblasts (Fig. 7F, 380 
row 1) with gene expression levels in HGPS compared to normal fibroblasts (Fig. 7F, 381 
row 2). This showed that 58% of the genes whose expression significantly increased or 382 
decreased upon TNPO1 depletion in normal fibroblasts showed a similar trend in 383 
control HGPS cells (Fig. 7F, compare genes that appear blue or red in both rows 1 and 384 
2). TNPO1 depletion can be expected to have differential effects compared to a change 385 
of TNPO1 sub-cellular localisation as observed in HGPS, where the protein is still 386 
expressed (Fig. 7A and TNPO1 gene indicated by a * on the heatmap Fig. 7F). 387 
Moreover, short-term TNPO1 depletion by siRNA might not recapitulate the effects of 388 
long-term decreased nuclear abundance of TNPO1 observed in HGPS cells. These 389 
results however support our hypothesis that the TNPO1 pathway is affected in HGPS 390 
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and that NAT10 inhibition mediates gene expression changes, at least in part through 391 
TNPO1. 392 
Collectively, these results suggested that NAT10 inhibition enhances global HGPS cell 393 
fitness by restoring TNPO1 function, thus rebalancing nucleo-cytoplasmic transport, 394 
restoring normal chromatin organization and control of gene expression, and thereby 395 




TNPO1 dysfunction in HGPS drives nuclear Ran defects. 399 
In this study, we established that the Transportin-1 pathway of nuclear import is 400 
mislocalized in cells derived from patients with Hutchinson-Gilford progeria syndrome. 401 
Furthermore, we found that defective nuclear import of TNPO1 cargo proteins 402 
including NUP153 (24) and hnRNPA1 (26) appeared to contribute to downstream 403 
phenotypic defects in HGPS cells, including abnormal nuclear pore assembly, 404 
chromatin disorganisation, gene expression changes and premature entry into 405 
senescence. While previous studies had reported RanGTP gradient defects in HGPS 406 
cells (9,10), the mechanism behind it was still unclear. Given the known link between 407 
oxidative stress and nucleo-cytoplasmic transport (as reviewed in (43)), and as 408 
oxidative stress is higher in HGPS cells (11), it was thought to be the main cause of 409 
decreased nuclear Ran abundance in progeria. However, oxidative stress has been 410 
shown to affect classical Importin nuclear import pathways (44), whereas we found 411 
here that the TNPO1 pathway appeared to be most affected in HGPS. Therefore, based 412 
on our findings herein, we suggest that depletion of Ran from the nucleus in HGPS 413 
cells is a consequence of dysfunctional TNPO1, rather than a direct effect of progerin 414 
expression, oxidative stress or NUP153 deregulation. In addition, by showing that 415 
NAT10 inhibition restores TNPO1 dependent nuclear import by releasing TNPO1 from 416 
the cytoplasm of HGPS cells, we have provided insights into how NAT10 inhibition, 417 
through its effects on microtubule stability, ameliorates cellular defects of HGPS cells. 418 
As described previously (21), NAT10 inhibition does not affect progerin expression or 419 
localisation, suggesting that its effects on HGPS cells occur through a progerin-420 
independent pathway.  421 
 422 
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It is still unclear how NAT10 activity might increase during normal and premature 423 
ageing. However, a recent study suggests that NAT10 activity is modulated by auto-424 
acetylation and that sirtuin proteins can mediate NAT10 deacetylation (45).  Sirtuin 425 
proteins have been linked to various age-related pathologies (reviewed in (46)), with 426 
their decreased activity being associated with senescence. In this context, reactivation 427 
of SIRT1 has been shown to extend health and lifespan in an HGPS mouse model (47). 428 
Therefore, we speculate that decreased sirtuin activity as occurs in aging might lead to 429 
increased NAT10 acetylation and activity, therefore contributing to increased 430 
microtubule stability. Whether the acetylation of other reported NAT10 substrates such 431 
as p53 (48), the upstream binding factor (UBF) (49) and rRNA (50) is also affected in 432 
HGPS is not known.  433 
 434 
Microtubule stability modulates nucleo-cytoplasmic transport. 435 
Based on our findings, we propose the following model depicted in Fig. 8 with NUP153 436 
as an example of a TNPO1 cargo protein. 1) In normal cells, microtubules bind to the 437 
nuclear pore complex (51) and TNPO1 binds to specific cargo proteins in the cytoplasm. 438 
2) The TNPO1-cargo protein complex is translocated into the nucleus through the 439 
nuclear pore. 3) Once in the nucleus and upon RanGTP binding to TNPO1, the NUP153 440 
cargo dissociates from TNPO1 and is incorporated as a component of the NPC basket 441 
structure, responsible for anchoring TPR (18,19), the last nucleoporin to be assembled 442 
(52). The resulting mature NPC is then fully functional for nucleocytoplasmic transport 443 
and other NPC-dependent roles. 4) During the progression of HGPS and during ageing 444 
of normal cells, increased microtubule network stability appears to sequester TNPO1 445 
in the cytoplasm. 5) As a consequence, TNPO1 cargos are not imported properly into 446 
the nucleus and one of these, NUP153, does not incorporate efficiently into nuclear 447 
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pore complexes. This results in decreased nuclear Ran abundance, as well as defects of 448 
TPR anchorage at nuclear pore complexes. Consequently, during the progression of 449 
HGPS and upon normal-cell ageing, there is progressive chromatin disorganisation and 450 
decompaction, global gene expression changes and premature entry into senescence. 451 
We speculate that the global deregulation of gene expression observed in HGPS cells 452 
is probably a consequence of both a direct effect of abnormal nuclear architecture on 453 
chromatin organisation, and of nucleo-cytoplasmic transport defects affecting the 454 
nuclear import of various proteins, including TPR that directly binds chromatin (38) 455 
and hnRNPA1 that modulates the activity of transcription factors (27-29). 6) By 456 
destabilising the microtubule network (21), NAT10 inhibition releases TNPO1 from 457 
the cytoplasm in HGPS or in normal cells from aged individuals, enhancing its nuclear 458 
translocation together with ensuing nuclear import of its cargos such as NUP153 and 459 
hnRNPA1. This then substantially normalizes normal chromatin organisation, Ran 460 
mediated nucleo-cytoplasmic transport and global transcription patterns. In support of 461 
this model, wherein NAT10 inhibition ameliorates HGPS phenotypes via the 462 
Transportin-1 pathway, we found that Remodelin had little effect on HGPS phenotypes 463 
when they had been depleted of TNPO1.  464 
 465 
In addition to helping to explain the mechanistic basis for HGPS cell dysfunction, our 466 
study highlights how specific components of the nucleo-cytoplasmic transport are 467 
affected by a range of factors, in this case cytoskeletal integrity. This correlates with a 468 
recent study showing that mechanical forces can modulate nuclear pore opening and 469 
conformation, thereby modifying nucleo-cytoplasmic transport efficiency (53). Finally, 470 
our study underscores the potential for NAT10 inhibition as a possible therapeutic 471 
strategy for HGPS, and perhaps also for certain pathologies associated with aging.   472 
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MATERIAL AND METHODS 473 
Cell culture and transfections. Normal skin primary fibroblasts from young healthy 474 
individual (GM03440, 20 years old), from Hutchinson-Gilford progeria syndrome 475 
(AG11498: 14 years old and AG11513: 8 years old) and from aged individuals 476 
(AG11240: 81 years old female, AG04059: 96 years old male, AG05248: 87 years old 477 
male, AG09602: 92 years old female) were purchased from Coriell Cell Repositories 478 
and used in passage matched-cells (unless indicated otherwise on the figure) between 479 
passage number 9-25. Cells were grown in Dulbecco’s modified Eagle medium 480 
(DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum (BioSera), 2mM 481 
L-glutamine, 100U per ml penicillin, 100 µg ml-1 streptomycin. Normal Retinal 482 
Pigmented Epithelial Cells (RPE-1) were grown in DMEM:F12 (Sigma-Aldrich) 483 
supplemented with 10% fetal bovine serum (BioSera), 2mM L-glutamine, 100U per ml 484 
penicillin, 100 µg ml-1 streptomycin. For serum starvation experiments, the same 485 
medium was used without any fetal bovine serum. The following siRNA duplexes were 486 
obtained from Life Sciences: NAT10 stealth RNAi: 487 
GAGCAUGGACCUCUCUGAAUACAUA, and as control siRNA, stealth RNAi 488 
negative control duplexes were used. TNPO1 siRNA were from Sigma Aldrich: 489 
GCAAAGAUGUACUCGUAAG, GUAUAGAGAUGCAGCCUUA and 490 
GUAAAUACCAGCAUAAGAA. Smart pool NUP153 and NTF2 small interfering 491 
RNA (siRNA) oligonucleotides where purchases from Dharmacon (Lafayette, USA). 492 
siRNA transfections were carried out using Lipofectamine RNAiMax (Life Sciences), 493 
following the manufacturer’s instructions. Cells were analysed 48 to 72 h after 494 
transfection. U2OS human osteosarcoma cells were grown in DMEM supplemented as 495 
above. Plasmid encoding the TNPO1 inhibitor Myc-MBP-M9M (40) was transfected 496 
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using Lipofectamine 2000 (Life Sciences), following the manufacturer’s instructions. 497 
Cells were analysed 24h after transfection.  498 
 499 
Cell proliferation. Non-transformed human RPE-1 cells were plated at equivalent low 500 
densities and transfected with control (siCT) or TNPO1 siRNA (siTNPO1) as explained 501 
above. Six days later, cells were fixed and stained with crystal violet staining solution 502 
(0.5% Crystal Violet, 20% methanol). 503 
 504 
Cell growth inhibition. RPE-1 cells or normal fibroblasts were either kept in normal 505 
medium supplemented with 10% fetal bovine serum (FBS) or in medium without serum 506 
to arrest cell proliferation. After 4 days of serum deprivation, cells were processed for 507 
immunofluorescence.  508 
 509 
Drug treatments. Remodelin was synthetized as described previously (21) incubated 510 
at 1 µM for at least 5 days, renewing the medium every 3 days. Long-term Remodelin 511 
treatment for microarray experiments was performed by keeping and passaging cells in 512 
medium containing 1 µM Remodelin or DMSO only for 12 population doublings. For 513 
immunofluorescence assays, Nocodazole and Tubacin were added to the medium for 514 
16h at 100ng/ml and 10µM respectively. 515 
 516 
Senescence assay. Senescence was assessed 72h after siRNA transfection using the 517 
Senescence β-Galactosidase Staining Kit #9860 from Cell Signaling. Blue cells were 518 
counted using the Cell counter plugin from Image J. 519 
 520 
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Immunoblotting. Total cell extracts were prepared by scraping cells in SDS lysis 521 
buffer (4% SDS, 20% glycerol, and 120 mM Tris-HCl, pH 6.8), boiling for 5 min at 522 
95°C, followed by 10 strokes through a 25-gauge needle. Before loading, lysates were 523 
diluted with a solution of 0.01% bromophenol blue and 200 mM DTT and boiled for 5 524 
min at 95°C. Proteins were resolved by SDS-PAGE on 4-12% gradient gels (NUPAGE, 525 
Life Sciences) and transferred onto nitrocellulose membrane (Protran; Whatman). 526 
Secondary antibodies conjugated to IRDye 800CW were from LI-COR Biosciences. 527 
Detection was performed with an imager (Odyssey; LI-COR Biosciences). 528 
 529 
Subcellular fractionation. Cells were harvested with trypsin-EDTA and centrifuged 530 
at 500xg for 5 min. Cells were washed once with 1ml ice-cold PBS and centrifuged at 531 
500xg for 5min. Supernatant was removed and 20µl of packed cell volume was 532 
processed for subcellular fractionation using the kit for cultured cells from 533 
ThermoFisher (Cat number 78840), using the manufacturer’s instructions. Subcellular 534 
fractions were then processed for immunoblotting as described above. Protein 535 
compartmentalisation in chromatin and cytoskeletal fractions was assessed by detection 536 
of the Histone H3 and alpha-Tubulin proteins. 537 
  538 
Immunofluorescence. Cells were washed with PBS and fixed for 20 min with 2% PFA 539 
in PBS. Cells were permeabilised for 5 min with PBS/0.2% Triton X-100, and blocked 540 
with PBS/0.2% Tween 20 (PBS-T) containing 5% BSA. Coverslips were incubated for 541 
1 h with primary antibodies and for 30 min with appropriate secondary antibodies 542 
coupled to Alexa Fluor 488, 594 or 647 fluorophores (Life Technologies), before being 543 
incubated with 2µg/ml DAPI. Pictures were acquired with a FluoView 1000 confocal 544 
microscope (Olympus) using the same laser power for matching images and antibodies. 545 
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All the immunofluorescence experiments were performed at least 3 times 546 
independently and the pictures shown in the figures are representative images of the 3 547 
experiments. Image analyses were carried out with the Volocity software (PerkinElmer) 548 
using the following protocol: Find objects (DAPI). Subpopulation: Fill holes in objects. 549 
Exclude touching edge of image. Exclude objects by size: <100µm2. Measure. The 550 
fluorescence intensity in each channel was then recorded.  551 
 552 
Proximity Ligation Assay (PLA). The PLA assays were carried out using the 553 
Duolink® In Situ Red Starter Kit Mouse/Rabbit (DUO9101, Sigma Aldrich) following 554 
manufacturer’s instructions. Image analysis was carried out with the Volocity software 555 
(PerkinElmer) using the following protocol: Find objects (DAPI). Exclude 556 
objects >1000µm2 and <20µm2. Fill holes in objects. Exclude touching edge of image. 557 
Find spots using intensity. Compartmentalize: Divide spots – Between nuclei. Select 558 
ROI and record the number of PLA spots.  559 
 560 
Antibodies. The following antibodies were used as indicated:  561 
Antibody Cat number Company Dilution WB Dilution IF 
α-tubulin  T9026 Sigma Aldrich 1/500 1/500 
Histone H3 ab1791 Abcam 1/1000 N/A 
H3K9me3 ab8898 Abcam 1/2000 1/1000 
TPR ab58344 Abcam 1/200 1/100 
TNPO1 ab10303 Abcam 1/200 1/200 
Lamin A/C  sc-6215 Santa Cruz 1/400 1/200 
NAT10 13365-1-AP ProteinTech 1/500 1/500 
hnRNPA1 4296 Cell Signaling 1/100 1/50 
Myc 2276 Cell Signaling N/A 1/5000 
NUP153 A301-788A Bethyl 1/200 1/100 
NUP153 MMS-102P Covance N/A 1/200 
Ran 610341 BD Biosciences 1/500 1/200 
 562 
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Micrococcal nuclease digestion sensitivity assay. As this assay requires a lot of cells, 563 
we could not perform it with HGPS cells and thus used human osteosarcoma U2OS 564 
cells instead. 1x106 cells were trypsinized, harvested, and washed once with 1ml of 565 
1xRSB buffer (10 mM Tris, pH 7.6, 15 mM NaCl, and 1.5 mM MgCl2). After 566 
centrifugation (300 x g), the cell pellet was resuspended in 1 ml of 1x RSB buffer with 567 
1% Triton-X 100 and homogenized by five strokes with a loose-fitting glass pestle to 568 
release nuclei. Nuclei were collected by centrifugation (13, 000 x g) and washed twice 569 
with 1 ml of buffer A (15 mM Tris, pH 7.5, 15 mM NaCl, 60 mM KCl, 0.34 M sucrose, 570 
0.5 mM spermidine, 0.15 mM spermine, 0.25 mM PMSF, and 0.1% b-571 
mercaptoethanol). Nuclei were resuspended in Buffer A and aliquoted into 100 µl 572 
aliquots. 1.2µl of 0.1 M CaCl2 was added to each aliquot and nuclei were digested by 573 
addition of 0.25 µl of 200 U/ml MNase (Sigma-Aldrich) and incubated at 30°C. Each 574 
aliquot was put back on ice at different time points and digestion was immediately 575 
stopped by addition of 3µl EDTA. DNA was purified using the Qiagen PCR 576 
purification kit and 1500 ng of DNA was analysed on a 1.5% agarose gel. Digestion 577 
profiles were analysed using ImageJ and values were adjusted relative to the global 578 
intensity of each lane to compensate for DNA loading variations.  579 
 580 
Microarray. Three independent biological replicates were used for each condition. 581 
RNA extracted from cells was purified using Direct-zol RNA MiniPrep kit (Zymo 582 
Research, cat. no. R2072) and treated with DNaseI (Zymo), according to manufacturers’ 583 
instructions. RNA quality was assessed using the Tapestation (Agilent Technologies) 584 
and Qubit (Invitrogen). Quality analysis of total RNA, hybridisation and data capture 585 
was performed at the Cambridge Genomic Services. Illumina HumanHT-12 v4 586 
beadchips were used for gene expression screening. Results were analysed using the 587 
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Lumi (54) Bioconductor package in R. Probe-level data were combined to give gene-588 
level data by taking the mean of all probes for a single gene. Differentially expressed 589 
genes were identified in each cell line using limma (55), using a 2-way factorial design 590 
with disease state as the first factor (HGPS vs normal fibroblasts) and treatment as the 591 
second factor (Remodelin vs DMSO, or siNAT10/siTNPO1/both vs siCT). 592 
Differentially expressed genes were calculated by performing pairwise comparisons 593 
between the four groups (Treated Normal, Untreated Normal, Treated HGPS, Untreated 594 
HGPS) for each treatment. All resulting p-values were corrected for multiple testing by 595 
using the Benjamini and Hochberg False Discovery Rate correction (52). Genes were 596 
defined as showing significantly altered expression if they showed a fold change greater 597 
than some threshold value (2-fold up or down for Remodelin, 1.5-fold up or down for 598 
siRNA) compared to control, with an adjusted p-value lower than 0.05.   599 
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SUPPLEMENTARY MATERIALS 600 
Fig. S1: TPR nuclear localisation is impaired in normal cells from aged individuals 601 
and normalised by NAT10 inhibition. 602 
Fig. S2: Nuclear import is affected in HGPS. 603 
Fig. S3: TNPO1 dependent protein cargos are affected in HGPS cells. 604 
Fig. S4: NAT10 nuclear import is not dependent on TNPO1. 605 
Fig. S5: Cell proliferation inhibition does not affect the Transportin-1 pathway. 606 
Fig. S6: NAT10 localises both in the nucleus and in the cytoskeleton. 607 
Fig. S7: TNPO1 accumulates at the microtubule network of HGPS cells. 608 
Fig. S8: TNPO1 pathway is defective in HGPS cells and in normal cells from aged 609 
individuals, and this is rescued by microtubule destabilization. 610 
Fig. S9: NUP153 depletion does not affect the Transportin-1 pathway. 611 
Fig. S10: Efficiency of protein depletions. 612 
Table S1: List of genes modified by Remodelin treatment 613 
Table S2: List of genes modified by NAT10 depletion 614 
Table S3: List of genes modified by TNPO1+NAT10 depletion 615 
Table S4: List of genes modified by TNPO1 depletion 616 





  622 
28	
REFERENCES AND NOTES 623 
1. De Sandre-Giovannoli, A., Bernard, R., Cau, P., Navarro, C., Amiel, J., 624 
Boccaccio, I., Lyonnet, S., Stewart, C. L., Munnich, A., Le Merrer, M., and 625 
Levy, N. (2003) Lamin a truncation in Hutchinson-Gilford progeria. Science 626 
300, 2055 627 
2. Eriksson, M., Brown, W. T., Gordon, L. B., Glynn, M. W., Singer, J., Scott, L., 628 
Erdos, M. R., Robbins, C. M., Moses, T. Y., Berglund, P., Dutra, A., Pak, E., 629 
Durkin, S., Csoka, A. B., Boehnke, M., Glover, T. W., and Collins, F. S. (2003) 630 
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford 631 
progeria syndrome. Nature 423, 293-298 632 
3. Goldman, R. D., Gruenbaum, Y., Moir, R. D., Shumaker, D. K., and Spann, T. 633 
P. (2002) Nuclear lamins: building blocks of nuclear architecture. Genes Dev 634 
16, 533-547 635 
4. Liu, B., Wang, J., Chan, K. M., Tjia, W. M., Deng, W., Guan, X., Huang, J. D., 636 
Li, K. M., Chau, P. Y., Chen, D. J., Pei, D., Pendas, A. M., Cadinanos, J., Lopez-637 
Otin, C., Tse, H. F., Hutchison, C., Chen, J., Cao, Y., Cheah, K. S., Tryggvason, 638 
K., and Zhou, Z. (2005) Genomic instability in laminopathy-based premature 639 
aging. Nat Med 11, 780-785 640 
5. Scaffidi, P., and Misteli, T. (2005) Reversal of the cellular phenotype in the 641 
premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11, 642 
440-445 643 
6. Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. 644 
(2013) The hallmarks of aging. Cell 153, 1194-1217 645 
7. Gordon, L. B., Massaro, J., D'Agostino, R. B., Sr., Campbell, S. E., Brazier, J., 646 
Brown, W. T., Kleinman, M. E., Kieran, M. W., and Progeria Clinical Trials, C. 647 
29	
(2014) Impact of farnesylation inhibitors on survival in Hutchinson-Gilford 648 
progeria syndrome. Circulation 130, 27-34 649 
8. Merideth, M. A., Gordon, L. B., Clauss, S., Sachdev, V., Smith, A. C., Perry, 650 
M. B., Brewer, C. C., Zalewski, C., Kim, H. J., Solomon, B., Brooks, B. P., 651 
Gerber, L. H., Turner, M. L., Domingo, D. L., Hart, T. C., Graf, J., Reynolds, J. 652 
C., Gropman, A., Yanovski, J. A., Gerhard-Herman, M., Collins, F. S., Nabel, 653 
E. G., Cannon, R. O., 3rd, Gahl, W. A., and Introne, W. J. (2008) Phenotype 654 
and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358, 592-655 
604 656 
9. Kelley, J. B., Datta, S., Snow, C. J., Chatterjee, M., Ni, L., Spencer, A., Yang, 657 
C. S., Cubenas-Potts, C., Matunis, M. J., and Paschal, B. M. (2011) The 658 
defective nuclear lamina in Hutchinson-gilford progeria syndrome disrupts the 659 
nucleocytoplasmic Ran gradient and inhibits nuclear localization of Ubc9. Mol 660 
Cell Biol 31, 3378-3395 661 
10. Snow, C. J., Dar, A., Dutta, A., Kehlenbach, R. H., and Paschal, B. M. (2013) 662 
Defective nuclear import of Tpr in Progeria reflects the Ran sensitivity of large 663 
cargo transport. J Cell Biol 201, 541-557 664 
11. Datta, S., Snow, C. J., and Paschal, B. M. (2014) A pathway linking oxidative 665 
stress and the Ran GTPase system in progeria. Mol Biol Cell 25, 1202-1215 666 
12. Gorlich, D., Pante, N., Kutay, U., Aebi, U., and Bischoff, F. R. (1996) 667 
Identification of different roles for RanGDP and RanGTP in nuclear protein 668 
import. Embo J 15, 5584-5594 669 
13. Bischoff, F. R., Klebe, C., Kretschmer, J., Wittinghofer, A., and Ponstingl, H. 670 
(1994) RanGAP1 induces GTPase activity of nuclear Ras-related Ran. Proc 671 
Natl Acad Sci U S A 91, 2587-2591 672 
30	
14. Bischoff, F. R., and Ponstingl, H. (1991) Catalysis of guanine nucleotide 673 
exchange on Ran by the mitotic regulator RCC1. Nature 354, 80-82 674 
15. Klebe, C., Bischoff, F. R., Ponstingl, H., and Wittinghofer, A. (1995) 675 
Interaction of the nuclear GTP-binding protein Ran with its regulatory proteins 676 
RCC1 and RanGAP1. Biochemistry 34, 639-647 677 
16. Hetzer, M., Gruss, O. J., and Mattaj, I. W. (2002) The Ran GTPase as a marker 678 
of chromosome position in spindle formation and nuclear envelope assembly. 679 
Nat Cell Biol 4, E177-184 680 
17. Izaurralde, E., Kutay, U., von Kobbe, C., Mattaj, I. W., and Gorlich, D. (1997) 681 
The asymmetric distribution of the constituents of the Ran system is essential 682 
for transport into and out of the nucleus. Embo J 16, 6535-6547 683 
18. Hase, M. E., and Cordes, V. C. (2003) Direct interaction with nup153 mediates 684 
binding of Tpr to the periphery of the nuclear pore complex. Mol Biol Cell 14, 685 
1923-1940 686 
19. Krull, S., Thyberg, J., Bjorkroth, B., Rackwitz, H. R., and Cordes, V. C. (2004) 687 
Nucleoporins as components of the nuclear pore complex core structure and Tpr 688 
as the architectural element of the nuclear basket. Mol Biol Cell 15, 4261-4277 689 
20. Cobb, A. M., Larrieu, D., Warren, D. T., Liu, Y., Srivastava, S., Smith, A. J., 690 
Bowater, R. P., Jackson, S. P., and Shanahan, C. M. (2016) Prelamin A impairs 691 
53BP1 nuclear entry by mislocalizing NUP153 and disrupting the Ran gradient. 692 
Aging Cell  693 
21. Larrieu, D., Britton, S., Demir, M., Rodriguez, R., and Jackson, S. P. (2014) 694 
Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science 695 
344, 527-532 696 
31	
22. Lau, C. K., Delmar, V. A., Chan, R. C., Phung, Q., Bernis, C., Fichtman, B., 697 
Rasala, B. A., and Forbes, D. J. (2009) Transportin regulates major mitotic 698 
assembly events: from spindle to nuclear pore assembly. Mol Biol Cell 20, 699 
4043-4058 700 
23. Shah, S., Tugendreich, S., and Forbes, D. (1998) Major binding sites for the 701 
nuclear import receptor are the internal nucleoporin Nup153 and the adjacent 702 
nuclear filament protein Tpr. J Cell Biol 141, 31-49 703 
24. Vollmer, B., Lorenz, M., Moreno-Andres, D., Bodenhofer, M., De Magistris, 704 
P., Astrinidis, S. A., Schooley, A., Flotenmeyer, M., Leptihn, S., and Antonin, 705 
W. (2015) Nup153 Recruits the Nup107-160 Complex to the Inner Nuclear 706 
Membrane for Interphasic Nuclear Pore Complex Assembly. Dev Cell 33, 717-707 
728 708 
25. Pollard, V. W., Michael, W. M., Nakielny, S., Siomi, M. C., Wang, F., and 709 
Dreyfuss, G. (1996) A novel receptor-mediated nuclear protein import pathway. 710 
Cell 86, 985-994 711 
26. Fridell, R. A., Truant, R., Thorne, L., Benson, R. E., and Cullen, B. R. (1997) 712 
Nuclear import of hnRNP A1 is mediated by a novel cellular cofactor related to 713 
karyopherin-beta. J Cell Sci 110 ( Pt 11), 1325-1331 714 
27. Dreyfuss, G., Matunis, M. J., Pinol-Roma, S., and Burd, C. G. (1993) hnRNP 715 
proteins and the biogenesis of mRNA. Annu Rev Biochem 62, 289-321 716 
28. Huelga, S. C., Vu, A. Q., Arnold, J. D., Liang, T. Y., Liu, P. P., Yan, B. Y., 717 
Donohue, J. P., Shiue, L., Hoon, S., Brenner, S., Ares, M., Jr., and Yeo, G. W. 718 
(2012) Integrative genome-wide analysis reveals cooperative regulation of 719 
alternative splicing by hnRNP proteins. Cell Rep 1, 167-178 720 
32	
29. Jean-Philippe, J., Paz, S., and Caputi, M. (2013) hnRNP A1: the Swiss army 721 
knife of gene expression. Int J Mol Sci 14, 18999-19024 722 
30. Moore, M. S. (1998) Ran and nuclear transport. J Biol Chem 273, 22857-22860 723 
31. Aliper, A. M., Csoka, A. B., Buzdin, A., Jetka, T., Roumiantsev, S., Moskalev, 724 
A., and Zhavoronkov, A. (2015) Signaling pathway activation drift during 725 
aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to 726 
normal middle-age and old-age cells. Aging (Albany NY) 7, 26-37 727 
32. Fredriksson, S., Gullberg, M., Jarvius, J., Olsson, C., Pietras, K., Gustafsdottir, 728 
S. M., Ostman, A., and Landegren, U. (2002) Protein detection using proximity-729 
dependent DNA ligation assays. Nature biotechnology 20, 473-477 730 
33. Smith, A., Brownawell, A., and Macara, I. G. (1998) Nuclear import of Ran is 731 
mediated by the transport factor NTF2. Curr Biol 8, 1403-1406 732 
34. Ribbeck, K., Lipowsky, G., Kent, H. M., Stewart, M., and Gorlich, D. (1998) 733 
NTF2 mediates nuclear import of Ran. Embo J 17, 6587-6598 734 
35. Csoka, A. B., English, S. B., Simkevich, C. P., Ginzinger, D. G., Butte, A. J., 735 
Schatten, G. P., Rothman, F. G., and Sedivy, J. M. (2004) Genome-scale 736 
expression profiling of Hutchinson-Gilford progeria syndrome reveals 737 
widespread transcriptional misregulation leading to mesodermal/mesenchymal 738 
defects and accelerated atherosclerosis. Aging Cell 3, 235-243 739 
36. Goldman, R. D., Shumaker, D. K., Erdos, M. R., Eriksson, M., Goldman, A. E., 740 
Gordon, L. B., Gruenbaum, Y., Khuon, S., Mendez, M., Varga, R., and Collins, 741 
F. S. (2004) Accumulation of mutant lamin A causes progressive changes in 742 
nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad 743 
Sci U S A 101, 8963-8968 744 
33	
37. Krull, S., Dorries, J., Boysen, B., Reidenbach, S., Magnius, L., Norder, H., 745 
Thyberg, J., and Cordes, V. C. (2010) Protein Tpr is required for establishing 746 
nuclear pore-associated zones of heterochromatin exclusion. Embo J 29, 1659-747 
1673 748 
38. Vaquerizas, J. M., Suyama, R., Kind, J., Miura, K., Luscombe, N. M., and 749 
Akhtar, A. (2010) Nuclear pore proteins nup153 and megator define 750 
transcriptionally active regions in the Drosophila genome. PLoS Genet 6, 751 
e1000846 752 
39. Guttinger, S., Muhlhausser, P., Koller-Eichhorn, R., Brennecke, J., and Kutay, 753 
U. (2004) Transportin2 functions as importin and mediates nuclear import of 754 
HuR. Proc Natl Acad Sci U S A 101, 2918-2923 755 
40. Cansizoglu, A. E., Lee, B. J., Zhang, Z. C., Fontoura, B. M., and Chook, Y. M. 756 
(2007) Structure-based design of a pathway-specific nuclear import inhibitor. 757 
Nat Struct Mol Biol 14, 452-454 758 
41. Marji, J., O'Donoghue, S. I., McClintock, D., Satagopam, V. P., Schneider, R., 759 
Ratner, D., Worman, H. J., Gordon, L. B., and Djabali, K. (2010) Defective 760 
lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal 761 
by farnesyltransferase inhibition. PLoS One 5, e11132 762 
42. Ito, S., Horikawa, S., Suzuki, T., Kawauchi, H., Tanaka, Y., Suzuki, T., and 763 
Suzuki, T. (2014) Human NAT10 is an ATP-dependent RNA acetyltransferase 764 
responsible for N4-acetylcytidine formation in 18 S ribosomal RNA (rRNA). J 765 
Biol Chem 289, 35724-35730 766 
43. Kodiha, M., and Stochaj, U. (2012) Nuclear transport: a switch for the oxidative 767 
stress-signaling circuit? J Signal Transduct 2012, 208650 768 
34	
44. Kodiha, M., Chu, A., Matusiewicz, N., and Stochaj, U. (2004) Multiple 769 
mechanisms promote the inhibition of classical nuclear import upon exposure 770 
to severe oxidative stress. Cell Death Differ 11, 862-874 771 
45. Cai, S., Liu, X., Zhang, C., Xing, B., and Du, X. (2017) Autoacetylation of 772 
NAT10 is critical for its function in rRNA transcription activation. Biochem 773 
Biophys Res Commun 483, 624-629 774 
46. Giblin, W., Skinner, M. E., and Lombard, D. B. (2014) Sirtuins: guardians of 775 
mammalian healthspan. Trends Genet 30, 271-286 776 
47. Liu, B., Ghosh, S., Yang, X., Zheng, H., Liu, X., Wang, Z., Jin, G., Zheng, B., 777 
Kennedy, B. K., Suh, Y., Kaeberlein, M., Tryggvason, K., and Zhou, Z. (2012) 778 
Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates 779 
progeroid features in laminopathy-based progeria. Cell Metab 16, 738-750 780 
48. Liu, X., Tan, Y., Zhang, C., Zhang, Y., Zhang, L., Ren, P., Deng, H., Luo, J., 781 
Ke, Y., and Du, X. (2016) NAT10 regulates p53 activation through acetylating 782 
p53 at K120 and ubiquitinating Mdm2. EMBO Rep 17, 349-366 783 
49. Kong, R., Zhang, L., Hu, L., Peng, Q., Han, W., Du, X., and Ke, Y. (2011) 784 
hALP, a novel transcriptional U three protein (t-UTP), activates RNA 785 
polymerase I transcription by binding and acetylating the upstream binding 786 
factor (UBF). J Biol Chem 286, 7139-7148 787 
50. Sharma, S., Langhendries, J. L., Watzinger, P., Kotter, P., Entian, K. D., and 788 
Lafontaine, D. L. (2015) Yeast Kre33 and human NAT10 are conserved 18S 789 
rRNA cytosine acetyltransferases that modify tRNAs assisted by the adaptor 790 
Tan1/THUMPD1. Nucleic acids research 43, 2242-2258 791 
51. Joseph, J., and Dasso, M. (2008) The nucleoporin Nup358 associates with and 792 
regulates interphase microtubules. FEBS Lett 582, 190-196 793 
35	
52. Bodoor, K., Shaikh, S., Salina, D., Raharjo, W. H., Bastos, R., Lohka, M., and 794 
Burke, B. (1999) Sequential recruitment of NPC proteins to the nuclear 795 
periphery at the end of mitosis. J Cell Sci 112 ( Pt 13), 2253-2264 796 
53. Elosegui-Artola, A., Andreu, I., Beedle, A. E. M., Lezamiz, A., Uroz, M., 797 
Kosmalska, A. J., Oria, R., Kechagia, J. Z., Rico-Lastres, P., Le Roux, A. L., 798 
Shanahan, C. M., Trepat, X., Navajas, D., Garcia-Manyes, S., and Roca-799 
Cusachs, P. (2017) Force Triggers YAP Nuclear Entry by Regulating Transport 800 
across Nuclear Pores. Cell 171, 1397-1410 e1314 801 
54. Du, P., Kibbe, W. A., and Lin, S. M. (2008) lumi: a pipeline for processing 802 
Illumina microarray. Bioinformatics 24, 1547-1548 803 
55. Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., and Smyth, 804 
G. K. (2015) limma powers differential expression analyses for RNA-805 
sequencing and microarray studies. Nucleic acids research 43, e47 806 
 807 
  808 
36	
Acknowledgments: We thank Dr Raphael Rodriguez (Curie Institute, Paris) for 809 
Remodelin synthesis, and Dr Yuh Min Chook for providing us with the plasmid 810 
encoding Myc-MBP-M9M. We thank Alison Schuldt and Kate Dry for critical reading 811 
of the manuscript. We thank all members of the Jackson lab, particularly J. Forment for 812 
discussions and comments. Funding: Research in the Jackson laboratory is funded by 813 
Cancer Research UK (CRUK) program grant C6/ A18796 and a Wellcome Trust 814 
Investigator Award (206388/Z/17/Z). Institute core funding is provided by CRUK 815 
(C6946/A24843) and the Wellcome Trust (WT203144). S.P.J. receives his salary from 816 
the University of Cambridge, UK. D.L was funded by a Project Grant from the Medical 817 
Research Council, UK MR/L019116/1 and is now funded, together with S.B., by a 818 
Wellcome Trust Henry Dale fellowship (86609). E.V., S.R. and the T.K. laboratory 819 
were supported by a grant from Cancer Research UK (Grant Reference RG17001) in 820 
addition to benefiting from core support from the Wellcome Trust (WT203144) and 821 
Cancer Research UK (C6946/A24843). TK is supported by a Cancer Research UK 822 
Gibbs Fellowship. Author contributions: DL designed, carried out and analysed all 823 
experiments, except the microarray and wrote the paper. EV carried out the microarray 824 
experiment and commented on the manuscript. SR analysed all microarray data, 825 
generated the corresponding graphs and legends. SB helped with revisions of the paper 826 
by repeating western blots. SPJ supervised the study and helped writing and editing the 827 
manuscript. TK commented on the manuscript. Competing interests: The authors 828 
declare that they have no competing interests. Data and materials availability: The 829 
raw data and processed differential expression tables from the microarray are available 830 
from ArrayExpress under accession number E-MTAB-6651 831 
(https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6651/).  832 
FIGURE LEGENDS 833 
 834 
37	
Figure 1: Nucleocytoplasmic transport is affected in aging and enhanced by 835 
NAT10 inhibition. (A) Representative immunofluorescence images from three 836 
independent experiments showing subcellular localisation of Ran in skin fibroblasts 837 
from a 20-year-old normal male (Normal fibro), aged individuals (AG11240, a 81-year-838 
old female; AG04059, a 96-year-old male; AG05248, a 87-year old-male; AG09602, a 839 
92-year-old female) or a 8-year-old HGPS patient (HGPS 11513). Scale bar: 50µm. (B) 840 
Representative Western blot from three independent experiments showing the 841 
abundance of the indicated proteins in extracts of young, aged and HGPS cells. (C) 842 
Representative immunofluorescence images from three independent experiments 843 
showing nuclear Ran and TPR in HGPS cells as compared to normal cells. Scale bar: 844 
50µm. (D) Quantification of TPR nuclear intensity in the indicated cells. (Mann 845 
Whitney test, number of nuclei n>100 from three independent experiments. Error bars 846 
indicate s.e.m. *p=0.016). (E) Representative immunofluorescence images from three 847 
independent experiments showing localization of NUP153 and TPR in normal 848 
fibroblasts (Normal Fibro) and fibroblasts from HGPS patients (HGPS 11513), in the 849 
absence (untreated) or presence of the NAT10 inhibitor Remodelin. Scale bar: 50µm. 850 
(F) Quantification of NUP153 and TPR nuclear intensity from experiments as shown 851 
in (E) (Mann Whitney test, number of nuclei n>70 from three independent experiments. 852 
Error bars indicate s.e.m. P values from left to right: *p=0.0111, ***p=0.0002, 853 
*p=0.0163, ***p=0.0007). (G) Proximity ligation assay (PLA) showing the interaction 854 
of TPR and NUP153 in normal and HGPS fibroblasts in the absence (untreated) or 855 
presence of the NAT10 inhibitor Remodelin (quantified in the right panel as the mean 856 
number of dots per nucleus; number of nuclei n>50 from three independent 857 
experiments). Scale bar: 50µm. (H) and (I) Ran nuclear localisation in HGPS cells upon 858 
depletion of NTF2 (siNTF2) or NAT10 (siNAT10) or upon NAT10 inhibition 859 
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(Remodelin). Scale bar: 50µm. (Mann Whitney test, number of nuclei n>70 from three 860 
independent experiments. Error bars indicate s.e.m. P values from left to right: 861 
**p=0.0043, ****p<0.0001, ns: non significant, ****p<0.0001, **p=0.0029). 862 
 863 
Figure 2: Disruption of Ran induces chromatin relaxation and senescence. (A) and 864 
(B) Analysis of chromatin relaxation by MNase assay in U2OS cells upon TPR 865 
depletion (siTPR) or disruption of Ran nuclear import by NTF2 depletion (siNTF2). 866 
Scale bar: 30µm. Digested chromatin was analysed on an agarose gel and quantified by 867 
using ImageJ. The graph is a representative figure of three independent experiments 868 
and represents the relative bands intensity (y axis) of the digested nucleosomes that 869 
migrate further from the well (x axis) as the chromatin is more relaxed, and thus more 870 
accessible to the MNase enzyme. (C) Representative immunofluorescence images from 871 
two independent experiments showing H3K9me3 staining in young (Normal Fibro, 872 
passage number (P) 19) or old (Normal Fibro P61) fibroblasts, as well as in HGPS cells, 873 
upon transfection with a control (siCT) or NTF2 siRNA (siNTF2) to disrupt the 874 
RanGTP gradient. (D) Quantification of H3K9me3 nuclear intensity from images as 875 
shown in C (Mann Whitney test, number of nuclei n>50 from two independent 876 
experiments. Error bars indicate s.e.m. P values from left to right: *p=0.0159, 877 
*p=0.014).  (E) Senescence associated β-galactosidase staining (blue cells) upon 878 
transfection with a control (siCT) or NTF2 (siNTF2) siRNA in normal (Normal fibro) 879 
and HGPS (HGPS 11513) fibroblasts at the indicated passage number (P). (F) 880 
Quantification of blue cells from experiments as shown in (C). Number of cells n>200 881 
from three independent experiments.  (Mann-Whitney test, P values from left to right: 882 
***p=0.0003, ***p=0.0002. Error bars indicate s.e.m.). 883 
 884 
39	
Figure 3: The Transportin-1 pathway is defective in HGPS cells and rescued by 885 
NAT10 inhibition. (A) Representative immunofluorescence images from three 886 
independent experiments showing the subcellular localization of TNPO1 and its 887 
downstream target hnRNPA1 in normal or HGPS fibroblasts in the absence (untreated) 888 
or presence of the NAT10 inhibitor Remodelin. Scale bar: 50µm. (B) Zoom-in images 889 
from panel (A) showing TNPO1 nuclear vs cytoplasmic subcellular localisation (scale 890 
bar: 50µm) as quantified in the bottom panel as nuclear-to-cytoplasmic ratio (N:C). 891 
Nuclei are outlined with white dotted lines. Box plots represent median (line), 10-90 892 
percentiles (whiskers) and outliers (dots). (Mann Whitney test, number of nuclei n>50 893 
from three independent experiments. P values from left to right: ****p<0.0001, 894 
***p=0.0003, ****p<0.0001, ns: non significant. Bars represent s.e.m.). (C) and (D). 895 
Representative immunofluorescence images from three independent experiments 896 
showing TNPO1 subcellular localisation in other HGPS fibroblasts (HGPS 11498) and 897 
in cells from normal aged individuals (AG11240 and AG059) (scale bar: 50µm). 898 
Overall TNPO1 and hnRNPA1 abundance is observed by western blotting (D) 899 
(representative image from three independent experiments).  900 
 901 
Figure 4: Microtubule reorganisation modulates TNPO1 localisation and function. 902 
(A) Proximity ligation assay (PLA) was performed using anti TNPO1 and alpha-tubulin 903 
antibodies. Representative immunofluorescence images from three independent 904 
experiments showing TNO1 and alpha-tubulin interaction. Each dot represents an 905 
interaction between one molecule of TNPO1 and one molecule of alpha-tubulin. Scale 906 
bars: 20µm. (B) Quantification of the PLA assay as shown in (A), representing both the 907 
total number of dots per cell (left graph) or the average number of spots in a set area of 908 
cytoplasm (Mann Whitney test, number of nuclei n>46 from three independent 909 
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experiments P values: ***p=0.0005, ***p=0.0003. Bars represent s.e.m.). (C) 910 
Representative immunofluorescence images from three independent experiments 911 
showing the effect of the destabilization (nocodazole) or stabilization (tubacin) of the 912 
microtubule network on the nuclear localization of TNPO1 and its downstream target 913 
hnRNPA1. Scale bar: 50µm. (D) Quantification of the TNPO1 nuclear-to-cytoplasmic 914 
ratio (N:C; top panel) and of hnRNPA1 nuclear intensity (bottom panel). Box plots 915 
represent median (line), 10-90 percentiles (whiskers) and outliers (dots). (Mann 916 
Whitney test, number of nuclei n>50 from three independent experiments. Top graph p 917 
values from left to right: **p=0.0011, ***p=0.0002,  ***p=0.0002, ns: non significant. 918 
Bottom graph p values from left to right: ***p=0.0002, ***p=0.0001, ***p=0.0001, 919 
**p=0.0023, ns: non significant. Bars represent s.e.m.). 920 
 921 
Figure 5: TNPO1 is required for cellular normalisations mediated by NAT10 922 
inhibition. (A) and (B) Representative immunofluorescence images from three 923 
independent experiments showing Ran and H3K9me3 staining in normal (A) or HGPS 924 
fibroblasts (B) after transfection with the indicated siRNA (see Fig. S10 for protein 925 
knock down efficiency). Scale bar: 50µm. (C) Quantification of H3K9me3 and Ran 926 
nuclear intensity from the cells as shown in A and B. (Unpaired t test, number of cells 927 
n>150 from three independent experiments. Error bars indicate s.e.m. P values from 928 
left to right: H3K9me3 Normal Fibroblasts: *p=0.0195, **p=0.0087, *p=0.0315, 929 
*p=0.0197, **p=0.0064. H3K9me3 HGPS: **p=0.0097, *p=0.03, *p=0.0393. Ran 930 
Normal Fibroblasts: *p=0.025, **p=0.0075, *p=0.0443, *p=0.011, *p=0.015. Ran 931 
HGPS: *p=0.0342, *p=0.0407, *p=0.0368.  (D) Quantification of senescence 932 
associated β-galactosidase (SA-β-Gal) staining (blue; E) in cells that had been treated 933 
with the indicated siRNAs. (Unpaired t test, number of cells n>200 from three 934 
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independent experiments. Error bars indicate s.e.m. P values from left to right: 935 
*p=0.0107, *p=0.049, ***p=0.0001, ****p<0.0001, ns: non significant). 936 
 937 
Figure 6: Effects of NAT10 inhibition or depletion on gene expression changes. (A) 938 
Volcano plots from the microarray analysis showing the number of genes whose 939 
expression was decreased (blue) or increased (red) under the indicated conditions. The 940 
log10 of the adjusted p-value is used such that the more significant a gene is, the higher 941 
it will be on the y-axis. The log2 of the fold change is used such that genes with 942 
increased or decreased expression have equal weighting on the figure. Using three 943 
biological replicates, genes were classed as showing gene expression changes if they 944 
were altered by 2-fold (up or down) or greater with an adjusted p value less than or 945 
equal to 0.05. For both normal and HGPS fibroblasts, Remodelin was used as a chronic 946 
treatment over eight weeks (middle and right panels). (B) Heat-maps of genes presented 947 
in (A) showing the effect of Remodelin treatment on gene expression in HGPS cells. 948 
(C) Volcano plots from the microarray analysis as presented in (A) and using three 949 
biological replicates, showing the number of genes whose expression was decreased 950 
(blue) or increased (red) by 1.5-fold or greater under the indicated conditions. NAT10 951 
depletion (siNAT10) was transient (5 days). (D) Heat-maps of genes presented in (C) 952 
showing the effect of NAT10 depletion on gene expression in HGPS cells.  953 
 954 
Figure 7: NAT10 modulates gene expression through TNPO1. (A) Representative 955 
Western blotting analysis from 2 independent experiments showing the efficiency of 956 
NAT10 (siNAT10) and TNPO1 (siTNPO1) depletion. (B) and (C) Venn diagrams from 957 
the microarray analysis showing the overlap between genes whose expression was 958 
significantly increased or decreased upon siNAT10 alone or together with siTNPO1 959 
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(siNAT10+siTNPO1). (D) Gene ontology analysis showing cellular component terms 960 
enrichment (CC) from genes whose expression was significantly decreased (blue) or 961 
increased (red) only upon siNAT10 in HGPS cells.  (E) Heat-maps of siNAT10 specific 962 
genes presented in (C) and (D), showing the gene expression changes for genes 963 
modified by siNAT10 only (compared to siCT) in HGPS cells (row 1) and their 964 
expression in HGPS cells compared to normal fibroblasts (row 2).  (F) Heat-maps of 965 
genes whose expression was significantly modified by TNPO1 depletion (siTNPO1) in 966 
normal fibroblasts (row 1), and their expression in HGPS cells compared to normal 967 
fibroblasts (row 2). TNPO1 is indicated by a *. Red indicates increased gene expression, 968 
whilst blue represents decreased gene expression. All these analyses were performed 969 
using three biological replicates. 970 
 971 
Figure 8: Model for how NAT10 inhibition rescues HGPS phenotypes. See main 972 
text for more details. 1) In normal cells, TNPO1 binds to its cargo proteins in the 973 
cytoplasm. 2) The TNPO1-cargo protein complex is translocated into the nucleus 974 
through the nuclear pore. 3) Once in the nucleus and upon RanGTP binding to TNPO1, 975 
the NUP153 cargo dissociates from TNPO1 and is incorporated into the nuclear pore 976 
complex, allowing TPR anchorage. Mature, fully functional nuclear pore complex 977 
regulates nucleocytoplasmic transport and other NPC-dependent roles. 4) In HGPS and 978 
aging, increased microtubule network stability sequesters TNPO1 in the cytoplasm. 5) 979 
TNPO1 cargos such as NUP153 are not imported properly into the nucleus. This results 980 
in decreased nuclear Ran abundance and defects of TPR anchorage at nuclear pore 981 
complexes. This leads to chromatin disorganisation, global gene expression changes 982 
and premature entry into senescence. 6) By destabilising the microtubule network, 983 
NAT10 inhibition releases TNPO1 from the cytoplasm, enhancing its nuclear 984 
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translocation together with ensuing nuclear import of its cargos such as NUP153 and 985 
hnRNPA1. This then substantially normalizes normal chromatin organisation, RanGTP 986 
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Figure S1: TPR nuclear localisation is impaired in normal cells from aged 27 
individuals and normalised by NAT10 inhibition. (A) Representative 28 
immunofluorescence pictures from three independent experiments showing nuclear 29 
localization of TPR in the indicated cells in the absence (top) or presence (bottom) of 30 
Remodelin. Scale bar: 50µm. (B) Quantification of TPR nuclear intensity from three 31 
independent experiments as shown in A (Unpaired t test, bars represent s.e.m. P values 32 




Figure S2: Nuclear import is affected in HGPS. (A) Representative 36 
immunofluorescence images (left) and quantification (right) of NUP153 (green) and 37 
TPR (red) staining from three independent experiments in normal fibroblasts or 38 
fibroblasts from HGPS patient 11498 (Unpaired t test, P values from left to right: 39 
*p=0.0354, *p=0.023) Bars represent s.e.m. (B) Representative immunofluorescence 40 
images (left) and quantification (right) of Ran from three independent experiments in 41 
normal fibroblasts or fibroblasts from HGPS patient 11498, in untreated cells or upon 42 
NAT10 inhibition by Remodelin (Unpaired t test, P values from left to right: 43 




Figure S3: TNPO1 dependent protein cargos are affected in HGPS cells. (A) 47 
Representative immunofluorescence images from three independent experiments 48 
showing the subcellular localisation of the NTF2 protein responsible for nuclear import 49 
of Ran. Scale bar: 50µm. (B) Representative immunofluorescence images from three 50 
independent experiments showing nuclear staining intensity of TNPO1 cargos 51 
including NUP153 and the Ewing sarcoma protein EWS in HGPS cells compared to 52 
controls. Scale bar: 50µm. (C) Quantification of EWS nuclear intensity in the indicated 53 
conditions (Unpaired t test from three independent experiments, bars represent s.e.m. P 54 




Figure S4: NAT10 nuclear import is not dependent on TNPO1. (A) Representative 58 
immunofluorescence images from thee independent experiments showing NAT10 59 
(green) and Ran (red) staining in both normal and HGPS fibroblasts. Scale bar: 50µm. 60 
(B) Human osteosarcoma U2OS cells were transfected with the plasmid encoding the 61 
TNPO1 inhibitor Myc-MBP-M9M (40) (red) to assess the effects on NAT10 nuclear 62 




Figure S5: Cell proliferation inhibition does not affect the Transportin-1 pathway. 66 
(A) Crystal violet staining of non-transformed human RPE-1 cells transfected with 67 
control (siCT) or TNPO1 siRNA (siTNPO1). Representative wells from three 68 
independent experiments are shown. (B) and (C) RPE-1 cells were either kept in normal 69 
or in medium without serum to arrest cell proliferation. Representative 70 
immunofluorescence images from three independent experiments showing staining of 71 
TNPO1 and its downstream cargo hnRNPA1 (B) as well as Ran and the 72 
heterochromatin marker H3K9me3 (C). (D) Normal fibroblasts were either kept in 73 
normal or in medium without serum to arrest cell proliferation. Representative 74 
immunofluorescence images from two independent experiments showing staining of 75 
TNPO1 and its downstream cargo hnRNPA1. Scale bars: 30µm. 76 
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 77 
Figure S6: NAT10 localises both in the nucleus and in the cytoskeleton. (A) 78 
Representative western blotting from two independent subcellular fractionations 79 
showing the abundance of the indicated proteins in the chromatin and cytoskeletal 80 
fractions of normal fibroblasts and HGPS cells in the absence (non treated, NT) or 81 
presence of Remodelin. (B) Representative immunofluorescence images from three 82 
independent experiments showing the subcellular localisation of NAT10 upon low 83 




Figure S7: TNPO1 accumulates at the microtubule network of HGPS cells. (A)  87 
Representative immunofluorescence images from three independent experiments 88 
showing the signal coming from the anti-TNPO1 (green) and anti-tubulin (red) 89 
antibodies used in the PLA assay. Scale bars: 50µm. (B) Representative Western 90 
blotting from three independent experiments showing the global abundance of the 91 
indicated proteins in normal vs HGPS cells. (C) Immunoprecipitation of TNPO1 in 92 
normal fibroblasts. 93 
 94 










































Figure S8: TNPO1 pathway is defective in HGPS cells and in normal cells from 97 
aged individuals, and this is rescued by microtubule destabilization. Representative 98 
immunofluorescence images (left) and quantification (right) from three independent 99 
experiments showing nuclear staining intensity of TNPO1 (red) and hnRNPA1 (green) 100 
in HGPS (HGPS11498) and in normal cells from aged individual (AG04059) treated 101 
with the indicated molecules. Scale bar: 50µm. (Unpaired t test, P values from left to 102 
right: ***p=0.0001, **p=0.0069, **p=0.0081, *p=0.0128, *p=0.0420, *p=0.0253. 103 




Figure S9: NUP153 depletion does not affect the Transportin-1 pathway. Normal 107 
Fibroblasts were transfected with the indicated siRNA before being stained for 108 
hnRNPA1 (green) and TNPO1 (red). Representative immunofluorescence images (left) 109 
from two independent experiments showing the effects of TNPO1 (siTNPO1) or 110 
NUP153 depletion (siNUP153) on the nuclear staining intensity of hnRNPA1. Scale 111 
bar: 50µm. Right: Quantification of hnRNPA1 nuclear intensity from two independent 112 
experiments in the indicated siRNA (Unpaired t test, P value: ***p=0.0004. Bars 113 












Figure S10: Efficiency of protein knock-down. The efficiency of the indicated 125 
siRNA was assessed by staining for the corresponding proteins. Representatives 126 
immunofluorescence images from three independent experiments are shown. Scale bar: 127 
50µm. 128 
